-
Axovant Sciences' Earnings Miss Takes A Backseat To Expected Pipeline Expansion
Tuesday, August 16, 2016 - 3:15pm | 436Read More...After the market closed on Monday, Axovant Sciences Ltd (NYSE: AXON) reported its second-quarter financial results, with a net loss of ($0.38) per share missing the Street’s consensus by $0.02 on the back of larger than expected SG&A expenses. However, JMP analysts Jason N. Butler and...
-
JMP: MannKind Investors Need 'Clarity'
Tuesday, March 15, 2016 - 10:36am | 247Read More...JMP’s Jason N. Butler reiterated a Market Perform rating on MannKind Corporation (NASDAQ: MNKD), while noting that “Afrezza remains in limbo as we await clarity on the commercialization plan and funding options.” Earnings Miss The company reported its 4Q15 earnings below the...
-
JMP Feeling Mostly Good On 4 Drug, Healthcare Stocks
Saturday, February 21, 2015 - 3:21pm | 333Read More...Four companies in the healthcare and pharmaceuticals sectors posted mixed results that left analysts at JMP Securities mostly feeling good. Adeptus Health Inc's (NYSE: ADPT) closed Friday up nearly 2 percent on strong quarterly results. JMP analyst Peter L. Martin expects Adeptus shares...
-
UPDATE: JMP Securities Reiterates On Esperion Therapeutics On Minimal Risks
Monday, January 5, 2015 - 11:00am | 191Read More...In a report published Monday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Esperion Therapeutics Inc (NASDAQ: ESPR), and raised the price target from $53.00 to $75.00. In the report, JMP Securities noted, “The completion of two-year carcinogenicity studies...
-
UPDATE: JMP Securities Reiterates On Esperion Therapeutics Inc Following Positive Trial Results
Thursday, October 2, 2014 - 10:05am | 188Read More...In a report published Thursday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Esperion Therapeutics Inc (NASDAQ: ESPR), and raised the price target from $34.00 to $53.00. In the report, JMP Securities noted, “ETC-1002 demonstrates compelling efficacy and safety...
-
UPDATE: JMP Securities Reiterates on Depomed Following Acquisition of Migraine Asset
Wednesday, December 18, 2013 - 10:35am | 172Read More...In a report published Wednesday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Depomed (NASDAQ: DEPO), and raised the price target from $10.00 to $11.00. In the report, JMP Securities noted, “Acquisition of migraine asset makes strategic and financial sense;...
-
UPDATE: JMP Securities Lowers PT on Aastrom Biosciences Following 2Q13 EPS Loss
Friday, August 16, 2013 - 11:05am | 201Read More...In a report published Friday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Aastrom Biosciences (NASDAQ: ASTM), but lowered the price target from $3.00 to $2.00. In the report, JMP Securities noted, “Progress continuing with enrollment in Phase 2b DCM trial;...
